Vyne Therapeutics INC Schedule 13G passive stakes

ADAR1 Capital Management, LLC and Daniel Schneeberger have jointly filed a Schedule 13G, reporting beneficial ownership of 8.8% of Yarrow Bioscience, Inc. common stock as of June 30, 2026.

Zhang Xiaofan has filed a Schedule 13G, reporting beneficial ownership of 0.6% of Yarrow Bioscience, Inc. common stock.

Logos Global Management LP and affiliated entities have reported an amendment to their Schedule 13G filing, detailing changes in their beneficial ownership of Yarrow Bioscience, Inc. common stock.

Janus Henderson Group Ltd. has disclosed beneficial ownership of 9.99% of Yarrow Bioscience, Inc.'s common stock, holding 266,712 shares and pre-funded warrants.

Logos Global Management LP and affiliated entities have reported beneficial ownership of 9.9% of Yarrow Bioscience, Inc. common stock, including shares and pre-funded warrants.

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have jointly filed a Schedule 13G, reporting beneficial ownership of 9.99% of Yarrow Bioscience, Inc.'s common stock.

RTW Fund Group GP, LLC and Roderick Wong, M.D. have reported beneficial ownership of 9.99% of Yarrow Bioscience, Inc. common stock.

Zhang Xiaofan has filed a Schedule 13G, reporting beneficial ownership of 16.5% of VYNE Therapeutics Inc. common stock.

Zhang Xiaofan has reported beneficial ownership of 4,595,118 shares, representing 13.8% of VYNE Therapeutics Inc.'s common stock, as of July 13, 2026.

Zhang Xiaofan has reported beneficial ownership of 1,873,388 shares, representing 5.6% of the outstanding common stock of VYNE Therapeutics Inc.

Nantahala Capital Management, LLC has reported a 6% beneficial ownership stake in VYNE Therapeutics Inc. as of March 31, 2026.

Citadel and its affiliates, including Kenneth Griffin, reported a 0.0% beneficial ownership in VYNE Therapeutics Inc. common stock in a recent Schedule 13G amendment.

Eventide Asset Management and its principals have filed an amended Schedule 13G, reporting zero beneficial ownership in VYNE Therapeutics Inc. common stock.

Cormorant Asset Management and Bihua Chen have reported a complete divestment of their beneficial ownership in VYNE Therapeutics Inc., now holding 0% of common stock.

Eventide Asset Management and associated individuals have disclosed a 9.99% beneficial ownership stake in VYNE Therapeutics Inc., including shares from pre-funded warrants.

Cormorant Asset Management and Bihua Chen report a combined 8.23% beneficial ownership stake in VYNE Therapeutics Inc., holding 1,370,938 shares.

Cormorant Asset Management, LP and Bihua Chen have filed an amended Schedule 13G, correcting their beneficial ownership in VYNE Therapeutics Inc. to 1,849,590 shares, representing 9.99% of the common stock.

Citadel Advisors LLC, Citadel Securities LLC, and affiliated entities, along with Kenneth Griffin, have disclosed their beneficial ownership in VYNE Therapeutics Inc., with Griffin's aggregate stake reaching 7.2% of the common stock.

Cormorant Asset Management, LP and Bihua Chen have filed an amended Schedule 13G, reporting 0% beneficial ownership of VYNE Therapeutics Inc. common stock, despite holding warrants exercisable for over 3 million shares, due to a contractual 9.99% exercise limitation.